Download Lecture 5 - Andrew.cmu.edu

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Complement system wikipedia , lookup

Adaptive immune system wikipedia , lookup

Duffy antigen system wikipedia , lookup

Immunoprecipitation wikipedia , lookup

DNA vaccination wikipedia , lookup

Adoptive cell transfer wikipedia , lookup

Multiple sclerosis research wikipedia , lookup

Anti-nuclear antibody wikipedia , lookup

Immunocontraception wikipedia , lookup

Immunomics wikipedia , lookup

Molecular mimicry wikipedia , lookup

Polyclonal B cell response wikipedia , lookup

ELISA wikipedia , lookup

Cancer immunotherapy wikipedia , lookup

Antibody wikipedia , lookup

Immunosuppressive drug wikipedia , lookup

Monoclonal antibody wikipedia , lookup

Transcript
03-131 Genes, Drugs, and Disease
Lecture 9
September 10, 2015
Lecture 9 - Antibody Structure & Protein-small Molecule Binding.
Disulfide bonds: These are covalent bonds between cysteine residues,
they crosslink the otherwise linear polypeptide chains. They increase
the stability of proteins and are often found on proteins that function Cysteine
outside of cells, such as antibodies.
Antibody (Ab, Ig) Structure:
Quaternary structure:
 2 Light + 2 heavy protein chains.
 Light chains are identical on any given Ab (~200 AA)
 Heavy chains are identical on any given Ab (~400 AA)
 Two binding sites/molecule
 Chains held together by
disulfide bonds (and noncovalent forces).
2H
Disulfide bond
Cysteine
Primary Structure (Amino acid
Sequence)
 The sequence of both chains
can be divided into a variable
and a constant region
 The sequence of the constant
region is the same on all light
chains and all heavy chains
(but the constant sequences
are different on light versus
heavy)
 The variable sequence is
different between antibodies
that bind different things.
 There are about 109 different
L+H variable sequences at any
given time, generated by a
fascinating random process.
 Each H &L variable sequence binds to a different antigen.
 The H & L variable sequences form the FV fragment.
NN-
N
N
...TSERTQYESTTY..
...AGLLITWHIKLPA...
N
N
CC
...LAERTYWHIKLPA...
N
N
CC
N
...AAFQRTYESTTY..
...FPREYAWHIKLPA...
C
N
...GVILPEEYESTTY..
N
CC
C
C C
C C
1
N
03-131 Genes, Drugs, and Disease
Lecture 9
September 10, 2015
Antibody-Antigen Interactions.
 A specific complex forms between the antigen and the antibody.
 This complex is stabilized by complementary interactions
between the antigen and amino acid residues from the antibody.
One, or more, of the following interactions can stabilize the
complex:
i) Hydrophobic effect – non-polar regions on antigens
ii) Hydrogen bonds – polar antigens with donors or acceptors.
iii) Van der Waals – shape complementarity
iv) Electrostatics – opposite charges attract!
Example, the complex between dinitrophenyl and an antibody:
DNP
Applications of Antibodies:
A) Drug detoxification – antibodies bind drugs, preventing them
from being toxic.
Trp90L DNP Trp100H
Glutamine
(LC)
B) Treatment of Cancer
Trade Name
Rituxan
Herceptin
Mylotarg*
Zevalin*
Bexxar*
Erbitux
Avastin
Used to Treat:
Non-Hodgkin lymphoma
Breast cancer
Acute myelogenous leukemia (AML)
Non-Hodgkin lymphoma
Non-Hodgkin lymphoma
Colorectal, Head & neck cancers
Colorectal cancer
Cancer cells eliminated by:
i) Antibody carries drug to target cell.
Approved in:
1997
1998
2000
2002
2003
2004, 2006
2004
ii) Antibody on surface causes the immune
system to destroy the target cell.
2